News

PipelineReview.com14h
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting
(“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that its research ...
PipelineReview.com15h
Strand Therapeutics Announces Initial First-in-human Phase 1 Data for STX-001 in Patients with Advanced Solid Tumors at The 2025 ASCO Annual Meeting
Favorable safety and tolerability, with promising early activity of novel mRNA-based therapy observed from interim data– ...
PipelineReview.com14h
Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash
BRANFORD, CT, USA I May 28, 2025 I Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies ...
PipelineReview.com15h
U.S. FDA Accepts New Drug Application Under Priority Review for sevabertinib (BAY 2927088) in HER2-Mutant Non-Small Cell Lung Cancer
WHIPPANY, NJ, USA I May 28, 2025 I Bayer announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application ...
PipelineReview.com15h
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
INDICATIONS AND USAGE TRYPTYR (acoltremon ophthalmic solution) 0.003% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).
PipelineReview.com14h
Kexing Biopharm’s GB18 project received clearance of IND application from NMPA and FDA
SHENZHEN, China I May 28, 2025 I On May 26th, Kexing Biopharm (688136.SH) announced that the National Medical Products Administration (NMPA) has approved ...